The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS - Acute lung injury
Publications
Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2001;7(10):552-60
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
The New England journal of medicine. 1980;303(4):183-8
Irreversible pulmonary toxicity after single course of BCNU.
The American journal of the medical sciences. 1980;279(1):53-6
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Cancer. 1984;54(4):751-5
Pulmonary toxicity from carmustine (BCNU): a case report.
Medical and pediatric oncology. 1979;6(3):255-9
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.
Cancer. 1979;43(5):1607-12
Multiple pulmonary lesions in a patient treated with BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) for glioblastoma multiforme.
Cancer. 1979;43(1):46-50